Denufosol
As of the edition of 20 October 2026, Denufosol is a small molecule: stopped in 2013; acts on P2RY2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2013
- Kind
- Small molecule
- Registered trials
- 16, 5 stopped early
- Disease areas
- Lungs and airways; Digestive system; Inherited and neonatal; Eye; Ear, nose and throat; Immune system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| P2RY2 | P2Y purinoceptor 2 | P41231 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 3 | 0 | 0 |
| Phase 2 | 10 | 6 | 0 | 4 |
| Phase 3 | 3 | 2 | 0 | 1 |
| All trials | 16 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Merck & Co. | Lead sponsor of trials | 2001 to now |